Tau Therapeutics, LLC and National Cancer Institute Launch Phase Ib Clinical Trial in Brain Cancer

CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--Tau Therapeutics LLC, a pharmaceutical company developing T-type calcium channel inhibitors for the treatment of solid tumors, announced today that it has opened enrollment for a Phase Ib clinical trial with the National Cancer Institute’s Adult Brain Tumor Consortium (ABTC) using the company’s first product candidate mibefradil. The trial will introduce a new therapeutic approach to patients with recurrent high-grade glioma.